

**ABSTRACT OF THE DISCLOSURE**

A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-  
5 CD22 or anti-CD37 antibody is provided.

0077038-04404